RESULTS WITH ACCELERATED PARTIAL BREAST IRRADIATION IN TERMS OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR, AND HUMAN GROWTH FACTOR RECEPTOR 2 STATUS

作者：Wilder Richard B^*; Curcio Lisa D; Khanijou Rajesh K; Eisner Martin E; Kakkis Jane L; Chittenden Lucy; Agustin Jeffrey; Lizarde Jessica; Mesa Albert V; Macedo Jorge C; Ravera John; Tokita Kenneth M

来源：International Journal of Radiation Oncology, Biology, Physics, 2010, 78(3): 799-803.

DOI：10.1016/j.ijrobp.2009.08.081

• Partial
• Breast
• Irradiation
• Triple
• Negative

Purpose: To report our results with accelerated partial breast irradiation (APBI) in terms of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) status.
Methods and Materials: Between February 2003 and June 2009, 209 women with early-stage breast carcinomas were treated with APBI using multicatheter, MammoSite, or Contura brachytherapy to 34 Gy in 10 fractions twice daily over 5-7 days. Three patient groups were defined by receptor status: Group 1: ER or PR (+) and HER-2/neu (-) (n = 180), Group 2: ER and PR (-) and HER-2/neu (+) (n = 10), and Group 3: ER, PR, and HER-2/neu (-) (triple negative breast cancer, n = 19). Median follow-up was 22 months.
Results: Group 3 patients had significantly higher Scarff-Bloom-Richardson scores (p < 0.001). The 3-year ipsilateral breast tumor control rates for Groups 1, 2, and 3 were 99%, 100%, and 100%, respectively (p = 0.15). Group 3 patients tended to experience relapse in distant sites earlier than did non Group 3 patients. The 3-year relapse-free survival rates for Groups 1, 2, and 3 were 100%, 100%, and 81%, respectively (p = 0.046). The 3-year cause-specific and overall survival rates for Groups 1, 2, and 3 were 100%, 100%, and 89%, respectively (p = 0.002).
Conclusions: Triple negative breast cancer patients typically have high-grade tumors with significantly worse relapse-free, cause-specific, and overall survival. Longer follow-up will help to determine whether these patients also have a higher risk of ipsilateral breast tumor relapse.

• 出版日期2010-11-1